A convertible bond offering helped knocked down Sarepta's shares this week. But with new drug trials set to begin, another insurer covering its stock, and ample cash on its balance sheet, the next move could be higher.
A convertible bond offering helped knocked down Sarepta's shares this week. But with new drug trials set to begin, another insurer covering its stock, and ample cash on its balance sheet, the next move could be higher.
Share this Article
Comment on this Article
Recommended
Please to comment